From Operating with Confidence Twenty years at Integra LifeSciences · · Princeton Engineering Lectures
“The company has raised close to $800 million to put all these acquisitions and product development in place. We did that through every possible avenue from banks, convertible bond holders, debt holders, equity holders, and warrant holders. You have to be as creative in your financial engineering to make a company like ours successful as you are in your product development.”
On , Stephen Leonard, Corporate Vice President of Global Operations & Supply Chain at INTEGRA LIFESCIENCES HOLDNGS, spoke about corporate finance during Operating with Confidence Twenty years at Integra LifeSciences on Princeton Engineering Lectures.
Stephen Leonard, Corporate Vice President of Global Operations & Supply Chain at Integra Lifesciences, has discussed the company's growth strategy and financial management. In a 2014 talk, he described how Integra combined acquisition-based growth with its core collagen technology, noting that "the combination of my background as a financier putting companies together from an acquisition perspective with the technological capabilities that Integra had was what enabled us to grow in the last 10 years." He stated that the company raised close to $800 million through various financial instruments, including banks, convertible bonds, debt, equity, and warrants, and emphasized the need for "creative financial engineering" alongside product development. Leonard also addressed product commercialization challenges. He said that Integra's artificial skin product was "extraordinary" clinically but "a disaster" commercially because the target market was initially wrong, and that the company later shifted focus to diabetic foot ulcers. He noted that when launching a dural patch product, the company changed its marketing strategy after learning that neurosurgeons valued the time savings of closing surgery 30 minutes faster over the regenerative benefits. Leonard added that Integra has few medical doctors on staff, instead partnering engineering teams with surgeons for product development.